|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
R, Torre L and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang H, Xu T, Huang Q, Jin W and Chen J:
Immunotherapy for malignant glioma: Current status and future
directions. Trends Pharmacol Sci. 41:123–138. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kong Z, Yan C, Zhu R, Wang J, Wang Y, Wang
Y, Wang R, Feng F and Ma W: Imaging biomarkers guided
anti-angiogenic therapy for malignant gliomas. Neuroimage Clin.
20:51–60. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Delgado-López P, Corrales-García E,
Martino J, Lastra-Aras E and Dueñas-Polo M: Diffuse low-grade
glioma: A review on the new molecular classification, natural
history and current management strategies. Clin Transl Oncol.
19:931–944. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ho VK, Reijneveld JC, Enting RH, Bienfait
HP, Robe P, Baumert BG and Visser O: Dutch Society for
Neuro-Oncology (LWNO). Changing incidence and improved survival of
gliomas. Eur J Cancer. 50:2309–2318. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Okuyama A, Shibata A and Nishimoto H:
Critical points for interpreting patients' survival rate using
cancer registries: A literature review. J Epidemiol. 28:61–66.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gao W, Li H, Liu Y, Zhang Y, Zhao H and
Liu F: Long non-coding RNA FLVCR1-AS1 promotes glioma cell
proliferation and invasion by negatively regulating miR-30b-3p. Mol
Med Rep. 22:723–732. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Vuong HG, Altibi AMA, Duong UNP, Ngo HTT,
Pham TQ, Chan AK, Park CK, Fung KM and Hassell L: TERT promoter
mutation and its interaction with IDH mutations in glioma: Combined
TERT promoter and IDH mutations stratifies lower-grade glioma into
distinct survival subgroups-a meta-analysis of aggregate data. Crit
Rev Oncol Hematol. 120:1–9. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ham SW, Jeon HY, Jin X, Kim EJ, Kim JK,
Shin YJ, Lee Y, Kim SH, Lee SY, Seo S, et al: TP53 Gain-of-function
mutation promotes inflammation in glioblastoma. Cell Death Differ.
26:409–425. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ostrom QT, Bauchet L, Davis FG, Deltour I,
Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh
KM, et al: The epidemiology of glioma in adults: A ‘state of the
science’ review. Neuro Oncol. 16:896–913. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Thomas P, Pranatharthi A, Ross C and
Srivastava S: RhoC: A fascinating journey from a cytoskeletal
organizer to a cancer stem cell therapeutic target. J Exp Clin
Cancer Res. 38(328)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wu Y, Chen Y, Sang J and Xu W: RhoC
protein stimulates migration of gastric cancer cells through
interaction with scaffold protein IQGAP1. Mol Med Rep. 4:697–703.
2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhao ZH, Tian Y, Yang JP, Zhou J and Chen
KS: RhoC, vascular endothelial growth factor and microvascular
density in esophageal squamous cell carcinoma. World J
Gastroenterol. 21:905–912. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yang H, Liang J, Zhou J, Mi J, Ma K, Fan
Y, Ning J, Wang C, Wei X and Li E: Knockdown of RHOC by shRNA
suppresses invasion and migration of cholangiocellular carcinoma
cells via inhibition of MMP2, MMP3, MMP9 and epithelial-mesenchymal
transition. Mol Med Rep. 13:5255–5261. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhao Y, Zong ZH and Xu HM: RhoC expression
level is correlated with the clinicopathological characteristics of
ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
Gynecol Oncol. 116:563–571. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang HZ, Liu JG, Wei YP, Wu C, Cao YK and
Wang M: Expression of G3BP and RhoC in esophageal squamous
carcinoma and their effect on prognosis. World J Gastroenterol.
13:4126–4130. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lang S, Busch H, Boerries M, Brummer T,
Timme S, Lassmann S, Aktories K and Schmidt G: Specific role of
RhoC in tumor invasion and metastasis. Oncotarget. 8:87364–87378.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Arisanty D, Harahap W, Khambri D, Rustam
R, Aliska G, Achyar A and Menra JP: The comparison of RhoC and PI3K
gene expression on the breast cancer tissue and benign tumour
tissue. Open Access Maced J Med Sci. 7:1911–1916. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Shen Y, Bu L, Li R, Chen Z, Tian F and Ge
Q: Expression and biological interaction network of RHOC for
hepatic carcinoma with metastasis in PBMC samples. Onco Targets
Ther. 12:9117–9128. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Bellovin DI, Simpson KJ, Danilov T,
Maynard E, Rimm DL, Oettgen P and Mercurio AM: Reciprocal
regulation of RhoA and RhoC characterizes the EMT and identifies
RhoC as a prognostic marker of colon carcinoma. Oncogene.
25:6959–6967. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang HB, Liu XP, Liang J, Yang K, Sui AH
and Liu YJ: Expression of RhoA and RhoC in colorectal carcinoma and
its relations with clinicopathological parameters. Clin Chem Lab
Med. 47:811–817. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Xie S, Zhu M, Lv G, Zhang Q and Wang G:
The role of RhoC in the proliferation and apoptosis of
hepatocellular carcinoma cells. Med Oncol. 29:1802–1809.
2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Tumur Z, Katebzadeh S, Guerra C, Bhushan
L, Alkam T and Henson BS: RhoC mediates epidermal growth
factor-stimulated migration and invasion in head and neck squamous
cell carcinoma. Neoplasia. 17:141–151. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Guo JQ, Zheng QH, Chen H, Chen L, Xu JB,
Chen MY, Lu D, Wang ZH, Tong HF and Lin S: Ginsenoside Rg3
inhibition of vasculogenic mimicry in pancreatic cancer through
downregulation of VE-cadherin/EphA2/MMP9/MMP2 expression. Int J
Oncol. 45:1065–1072. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kleer CG, Griffith KA, Sabel MS, Gallagher
G, van Golen KL, Wu ZF and Merajver SD: RhoC-GTPase is a novel
tissue biomarker associated with biologically aggressive carcinomas
of the breast. Breast Cancer Res Treat. 93:101–110. 2005.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhang HJ, Tao J, Sheng L, Hu X, Rong RM,
Xu M and Zhu TY: Twist2 promotes kidney cancer cell proliferation
and invasion by regulating ITGA6 and CD44 expression in the
ECM-receptor interaction pathway. Onco Targets Ther. 9:1801–1812.
2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liu Z, Shen F, Wang H, Li A, Wang J, Du L,
Liu B, Zhang B, Lian X, Pang B, et al: Abnormally high expression
of HOXA2 as an independent factor for poor prognosis in glioma
patients. Cell Cycle. 19:1632–1640. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sloan KE, Stewart JK, Treloar AF, Matthews
RT and Jay DG: CD155/PVR enhances glioma cell dispersal by
regulating adhesion signaling and focal adhesion dynamics. Cancer
Res. 65:10930–10937. 2005.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Fan Y, Potdar AA, Gong Y, Eswarappa SM,
Donnola S, Lathia JD, Hambardzumyan D, Rich JN and Fox PL:
Profilin-1 phosphorylation directs angiocrine expression and
glioblastoma progression through HIF-1α accumulation. Nat Cell
Biol. 16:445–456. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Mure H, Matsuzaki K, Kitazato KT,
Mizobuchi Y, Kuwayama K, Kageji T and Nagahiro S: Akt2 and Akt3
play a pivotal role in malignant gliomas. Neuro Oncol. 12:221–232.
2010.PubMed/NCBI View Article : Google Scholar
|
